Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5122 Target Snapshot

Discoidin domain-containing receptor 2 · SINGLE PROTEIN · Homo sapiens

1,492Compounds
383Assays
26Approved Drugs
874.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16832. Start with cancer, then reuse UniProt Q16832 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt Q16832 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Discoidin domain-containing receptor 2 as ChEMBL target CHEMBL5122, mapped to UniProt Q16832. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Discoidin domain-containing receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5122
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16832
Discoidin domain-containing receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Discoidin domain-containing receptor 2 is the right protein anchor across sources, using UniProt Q16832 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDiscoidin domain-containing receptor 2
UniProt AccessionQ16832
Component TypeProtein
Sequence Length855 aa

Discoidin domain-containing receptor 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Discoidin domain-containing receptor 2, mapped to UniProt Q16832. Sequence length is 855 aa.

Mapped IDQ16832
Review nameDiscoidin domain-containing receptor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Discoidin domain-containing receptor 2 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
colorectal neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugREGORAFENIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include REGORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

26
Approved
8
Phase III
27
Phase II
8
Phase I
Assay Mix

Activity Type Distribution

IC50447.0
EC502.0
KD425.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5938192 11.0 IC50 0.01 Preclinical
CHEMBL5781115 10.0 IC50 0.1 Preclinical
CHEMBL5787536 10.0 IC50 0.1 Preclinical
CHEMBL5965095 10.0 IC50 0.1 Preclinical
CHEMBL5756960 9.7 IC50 0.2 Preclinical
CHEMBL5885968 9.7 IC50 0.2 Preclinical
CHEMBL6051298 9.7 IC50 0.2 Preclinical
CHEMBL6055194 9.52 IC50 0.3 Preclinical
CHEMBL6027087 9.52 IC50 0.3 Preclinical
CHEMBL6052146 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
67
5.5
83
6.0
67
6.5
74
7.0
45
7.5
68
8.0
29
8.5
16
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
QUIZARTINIB
CHEMBL576982
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
TIVOZANIB
CHEMBL1289494
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
CABOZANTINIB
CHEMBL2105717
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

383
Total Assays
425
Tested Compounds
2
Assay Types
Binding — 380 assays, 425 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 285 257 7.2
assay format 54 87 6.3
cell-based format 40 37 6.5
subcellular format 1 44 6.2
ADME — 3 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 7 6.6
cell-based format 1 0
single protein format 1 1 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine